Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 241K | 20K | 100K | 42K | 0 |
| Gross Profit | 62K | 8K | 5K | 3K | 0 |
| Operating Income | -546K | -15M | -7M | -33K | -91K |
| EBITDA | -532K | -15M | -7M | 0 | 0 |
| Net Income | -536K | -15M | -7M | -34K | -100K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.50
+0.00% today
1Y Change
-62.50%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 253 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Panamera Holdings Corporation (PHCI) is a Healthcare stock with a market cap of $370.00M and listed on OTC. The stock last traded around $1.50 and down 62.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +1129.1%, EPS growth of +96.9%, a dividend yield of 0.0%. What stands out right now is revenue +1129.1%, EPS +96.9%, free cash flow -418.5% with operating margin -51672.8% and ROIC 3783.0%. Valuation already assumes a fairly strong business story at price/sales 1239.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PHCI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHCI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHCI Max Drawdown
-85.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHCI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$100.0K
-193.6% YoY
Free Cash Flow
-$99.4K
-239.6% YoY
Revenue Growth
+1129.1%
EPS Growth
+96.9%
Gross Margin
34.4%
Net Margin
-51700.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 241K | 20K | 100K | 42K | 0 |
| Gross Profit | 62K | 8K | 5K | 3K | 0 |
| Operating Income | -546K | -15M | -7M | -33K | -91K |
| EBITDA | -532K | -15M | -7M | 0 | 0 |
| Net Income | -536K | -15M | -7M | -34K | -100K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86K | 2K | 119K | 3K | 10 |
| Total Assets | 804K | 106K | 130K | 13K | 10 |
| Total Liabilities | 179K | 288K | 80K | 60K | 15K |
| Shareholder Equity | 624K | -182K | 50K | -48K | -15K |
| Total Debt | 81K | 184K | 47K | 34K | 2K |
| Net Debt | -5K | 182K | -71K | 31K | 2K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
99K
-239.6% YoY
Capital Expenditures
0
Free Cash Flow
99K
-239.6% YoY
Key ratios
Gross Margin
34.4%
Operating Margin
-51672.8%
Net Margin
-51700.6%
ROE
8214.1%
Debt / Equity
-0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.